摘要
心血管代谢性疾病(cardiometabolic disease,CMD)是指代谢系统和心血管系统单一或者同时发生、可相互影响的病理改变,是代谢性疾病和心血管疾病的总称。包括肥胖、胰岛素抵抗、代谢综合征、糖尿病以及冠心病等。脂肪因子在CMD的发生发展中发挥关键性作用。补体C1q肿瘤坏死因子相关蛋白7(complement C1q TNF-related protein 7,CTRP7)是新近发现的脂肪因子,与肥胖、糖尿病及冠心病等CMD密切相关。本文围绕CTRP7生物学特性,综述其在CMD(包括肥胖、2型糖尿病和冠心病)发生发展中的作用,及可能的作用机制如多种途径调控糖脂代谢、降低胰岛素敏感性、促进炎症反应和增加氧化应激等,以期为CTRP7作为CMD的治疗靶标提供依据和参考。
Cardiometabolic disease(CMD)refers to the single or simultaneous occurrence of pathological changes in the metabolic and cardiovascular systems that can mutually influence each other,which is a collective term for metabolic and cardiovascular diseases,including obesity,insulin resistance,metabolic syndrome,diabetes,and coronary heart disease,etc.Adipokines play a critical role in the occurrence and development of CMD.Complement C1q TNF-related protein 7(CTRP7)is a recently discovered adipokine closely associated with CMD,such as obesity,diabetes and coronary heart disease.Focusing on the biological characteristics of CTRP7,this article reviews its role in the occurrence and development of CMD,including obesity,type 2 diabetes mellitus and coronary heart disease,as well as the possible mechanisms such as regulating glucose and lipid metabolism,decreasing insulin sensitivity,promoting inflammatory responses and increasing oxidative stress,so as to provide evidence and references for CTRP7 as a therapeutic target of CMD.
作者
李定微
钱帅伟
李春艳
LI Ding-Wei;QIAN Shuai-Wei;LI Chun-Yan(Department of Sports Medicine,Wuhan Sports University,Wuhan 430070,China;Hubei Key Laboratory of Sports Training Monitoring,Wuhan 430070,China)
出处
《生理科学进展》
CAS
北大核心
2024年第2期126-132,共7页
Progress in Physiological Sciences
基金
2022年教育部人文社会科学基金(22YJCZH138)
武汉体育学院中青年科研团队(21KT11)资助课题。
